Dr. Janet Dancey is the Director of the Canadian Cancer Trials Group, also known as the CCTG, and a Professor in the Department of Oncology at Queen’s. She is also the Director of the High Impact Clinical Trials Program at the Ontario Institute for Cancer Research. The CCTG has over 80 member institutions, comprising over 2100 Canadian investigators who have facilitated over 500 trials in more than 40 countries. They are also the only non-American partner of the US National Clinical Trials Network.

Prior to joining the CCTG, Dr. Dancey was Senior Clinical Investigator in the Cancer Therapy Evaluation Program at the US National Cancer Institute and then Associate Chief of the Investigational Drug Branch.  Her expertise lies in anti-cancer drug development, linking drug and biomarker development, and associated clinical trials methodology.

In this episode, she discusses the importance of clinical trials and breaks down their evolved and enhanced process for drug development and delivery. Dr. Dancey also explains that the collaborative study of medical interventions in the treatment of cancer have expanded to also investigate how lifestyle, radiation, surgical, and smoke cessation interventions can affect the entire spectrum of cancer treatment.

Please visit the Department of Oncology or the Canadian Cancer Trials Group for more information about Dr. Dancey's research.